Clinical Trial Update: BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating BCMA-targeted LCAR-BCDR Cells in patients with relapsed/refractory multiple myeloma has been terminated (status TERMINATED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LCAR-BCDR Cells (LCAR-BCDR Cells)

Snippet

Sponsor: Weijun Fu | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED